CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc

Oncotarget

Volumn 6, Issue 38, 2015, Pages 40775-40798

  Pu, Hu ^a   Zheng, Qidi ^a   Li, Haiyan ^a   Wu, Mengying ^a   An, Jiahui ^a   Gui, Xin ^a   Li, Tianming ^a   Lu, Dongdong ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

CUDR; Liver cancer stem cell; PTEN

Indexed keywords

CD133 ANTIGEN; CD24 ANTIGEN; CYCLIN D1; DNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNTRANSLATED RNA; LONG UNTRANSLATED RNA; MESSENGER RNA; MYC PROTEIN, HUMAN; TERT PROTEIN, HUMAN; UCA1 RNA, HUMAN;

ARTICLE; CANCER GROWTH; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; CUDR GENE; DNA METHYLATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL; MALIGNANT TRANSFORMATION; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN FUNCTION; UPREGULATION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, LONG NONCODING; RNA, MESSENGER; TELOMERASE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84951133237     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5805     Document Type: Article

References (47)

1. M. G. Slomiany, L. Dai, L. B. Tolliver, G. D. Grass, Y. Zeng, and B. P. Toole. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clinical Cancer Research. 2009; 15:7593-7601.
2. H. J. Lee, G. Choe, S. Jheon, S.W. Sung, C.T. Lee, and J.H. Chung. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (Seventh) New TNM classification. Journal of Thoracic Oncology. 2010; 5:649-657.
3. E. L. H. Leung, R. R. Fiscus, J. W. Tung. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS ONE. 2010; 5:e14062.
4. L. Du, H. Wang, L. He. CD44 is of functional importance for colorectal cancer stem cells. Clinical Cancer Research. 2008; 14:6751-6760.
5. L. Zhou, Y. Jiang, T. Yan. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Research and Treatment. 2010; 122:795-801.
6. Q. Ji, X. Hao, M. Zhang. MicroRNA miR-3 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE. 2009; 4:e6816.
7. Y. Wu and P.Y. Wu. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells and Development. 2009; 18:1127-1134.
8. H Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013; 339:159-66.
9. Han Y, Yang YN, Yuan HH, Zhang TT, Sui H, Wei XL, Liu L, Huang P, Zhang WJ, Bai YX. UCA1, a long noncoding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology. 2014; 46:396-401.
10. Xue M, Li X, Li Z, Chen W. Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1a-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion. Tumour Biol. 2014; 35:6901-12.
11. Kumar P P, Emechebe U, Smith R, Franklin S, Moore B, Yandell M, Lessnick SL, Moon AM. Coordinated control of senescence by lncRNA and a novel T-box3 co-repressor complex. Elife. 2014;:e02805.
12. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 2014; 281:1750-8.
13. Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu M, Mo YY. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis. 2014; 5:e1008.
14. Liu SP, Yang JX, Cao DY, Shen K. Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials. Cancer Biol Med. 2013; 10:138-41.
15. Fang Z, Wu L, Wang L, Yang Y, Meng Y, Yang H. Increased expression of the long non-coding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 117:89-95.
16. Kaneko K, Ito Y, Ono Y, Tainaka T, Tsuchiya H, Shimoyama Y, Ando H. Gene expression profiling reveals upregulated UCA1 and BMF in gallbladder epithelia of children with pancreaticobiliary maljunction. J Pediatr Gastroenterol Nutr. 2011; 52:744-50.
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275:1943-1947.
18. Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M, Miyazaki J, Suda T, Itoh H, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev. 2005; 19:2054-65.
19. Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem J. 2004; 382:1-11.
20. Ji S-P, Zhang Y, Cleemput JV, Jiang W, Liao M, Li L, Wan Q, Backstrom JR, Zhang X. Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abus. Nature Medicine. 2006; 12:324-9.
21. Poliseno L, Pandolfi PP. PTEN ceRNA networks in human cancer. Methods. 2015; 77-78:41-50.
22. Li E, Xu Z, Zhao H, Sun Z, Wang L, Guo Z, Zhao Y, Gao Z, Wang Q. Macrophages promote benzopyreneinduced tumor transformation of human bronchial epithelial cells by activation of NF-κB and STAT3 signaling in a bionic airway chip culture and in animal models. Oncotarget. 2015; 6:8900-13.
23. Hou ZJ, Luo X, Zhang W, Peng F, Cui B, Wu SJ, Zheng FM, Xu J, Xu LZ, Long ZJ, Wang XT, Li GH, Wan XY, et al. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget. 2015; 6:6326-40.
24. Zhou Y, Liang C, Xue F, Chen W, Zhi X, Feng X, Bai X, Liang T. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. Oncotarget. 2015; 6:10350-65.
25. Wang J, Liu M, Chen L, Chan TH, Jiang L, Yuan YF, Guan XY. Overexpression of N-terminal kinase like gene promotes tumorigenicity of hepatocellular carcinoma by regulating cell cycle progression and cell motility. Oncotarget. 2015; 6:1618-30.
26. Pibouin L, Villaudy J, Ferbus D, Muleris M, Prospéri MT, Remvikos Y, Goubin G. Cloning of the mRNA of overexpression in colon carcinoma-1: a sequence overexpressed in a subset of colon carcinomas. Cancer Genet Cytogenet. 2002; 133:55-60.
27. Yang C, Li X, Wang Y, Zhao L, Chen W. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene. 2012; 496:8-16.
28. Takeuchi S, Hofmann WK, Tsukasaki K, et al. Loss of H19 imprinting in adult T-cell leukaemia/lymphoma". Br. J. Haematol. 2007; 137:380-1.
29. Arima T, Matsuda T, Takagi N, Wake N. Association of IGF2 and H19 imprinting with choriocarcinoma development. Cancer Genet. Cytogenet. 1997; 93:39-47.
30. Banet G, Bibi O, Matouk I. Characterization of human and mouse H19 regulatory sequences. Mol. Biol. Rep. 2000; 27:157-65.
31. Tanos V, Ariel I, Prus D, De-Groot N, Hochberg A. H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium. Int. J. Gynecol. Cancer. 2004; 14:521-5.
32. Gao ZH, Suppola S, Liu J, Heikkilä P, Jänne J, Voutilainen R. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. J. Clin. Endocrinol. Metab. 2002; 87:1170-6.
33. Lottin S, Adriaenssens E, Dupressoir T, Berteaux N, Montpellier C, Coll J, Dugimont T, Curgy JJ. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis. 2002; 23:1885-95.
34. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, Tsao MS, Penn LZ. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res. 2006; 66:5330-7.
35. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE. 2007; 2:e845.
36. Li H, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014; 5:2318-29.
37. Venkatraman A, He XC, Thorvaldsen JL, Sugimura R, Perry JM, Tao F, Zhao M, Christenson MK, Sanchez R, Yu JY, Peng L, Haug JS, Paulson A, et al. Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature. 2013; 500:345-9.
38. Medrzycki M, Zhang Y, Zhang W, Cao K, Pan C, Lailler N, McDonald JF, Bouhassira EE, Fan Y. Histone h1.3 suppresses h19 noncoding RNA expression and cell growth of ovarian cancer cells. Cancer Res. 2014; 74:6463-73.
39. Kim H, Yoo JE, Cho JY, Oh BK, Yoon YS, Han HS, Lee HS, Jang JJ, Jeong SH, Kim JW, Park YN. Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing "stemness"-related markers. J Hepatol. 2013; 59:746-52.
40. Porro A, Feuerhahn S, Delafontaine J, Riethman H, Rougemont J, Lingner J. Functional characterization of the TERRA transcriptome at damaged telomeres. Nat Commun. 2014; 5:5379.
41. Biffi G, Tannahill D, Balasubramanian S. An intramolecular G-quadruplex structure is required for binding of telomeric repeat-containing RNA to the telomeric protein TRF2. J Am Chem Soc. 2012; 134:11974-6.
42. Poulet A, Pisano S, Faivre-Moskalenko C, Pei B, Tauran Y, Haftek-Terreau Z, Brunet F, Le Bihan YV, Ledu MH, Montel F, Hugo N, Amiard S, Argoul F, et al. The N-terminal domains of TRF1 and TRF2 regulate their ability to condense telomeric DNA. Nucleic Acids Res. 2012; 40:2566-76.
43. Nativio R, Wendt KS, Ito Y, Huddleston JE, Uribe-Lewis S, Woodfine K, Krueger C, Reik W, Peters JM, Murrell A. Cohesin is required for higher-order chromatin conformation at the imprinted IGF2-H19 locus. PLoS Genet. 2009; 5:e1000739.
44. Merkenschlager M, Odom DT. CTCF and cohesin: linking gene regulatory elements with their targets. Cell. 2013; 152:1285-97.
45. Wen B, Wu H, Loh YH, Briem E, Daley GQ, Feinberg AP. Euchromatin islands in large heterochromatin domains are enriched for CTCF binding and differentially DNAmethylated regions. BMC Genomics. 2012; 13:566.
46. Deng Z, Wang Z, Stong N, Plasschaert R, Moczan A, Chen HS, Hu S, Wikramasinghe P, Davuluri RV, Bartolomei MS, Riethman H, Lieberman PM. A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection. EMBO J. 2012; 31:4165-78.
47. Lin S, Ferguson-Smith AC, Schultz RM, Bartolomei MS. Nonallelic transcriptional roles of CTCF and cohesins at imprinted loci. Mol Cell Biol. 2011; 31:3094-104.